Moderated ionic bonding for water-free recyclable polyelectrolyte complex materials.

While nature extensively uses electrostatic bonding between oppositely charged polymers to assemble and stabilize materials, harnessing these interactions in synthetic systems has been challenging. Synthetic materials cross-linked with a high density of ionic bonds, such as polyelectrolyte complexes, only function properly when their charge interactions are attenuated in the presence of ample amounts of water; dehydrating these materials creates such strong Coulombic bonding that they become brittle, non-thermoplastic, and virtually impossible to process. We present a strategy to intrinsically moderate the electrostatic bond strengths in apolar polymeric solids by the covalent grafting of attenuator spacers to the charge carrying moieties. This produces a class of polyelectrolyte materials that have a charge density of 100%, are processable and malleable without requiring water, are highly solvent- and water-resistant, and are fully recyclable. These materials, which we coin "compleximers," marry the properties of thermoplastics and thermosets using tailored ionic bonding alone.

Ultrafast optical circuit switching for data centers using integrated soliton microcombs.

Due to the slowdown of Moore's law, it will become increasingly challenging to efficiently scale the network in current data centers utilizing electrical packet switches as data rates grow. Optical circuit switches (OCS) represent an appealing option to overcome this issue by eliminating the need for expensive and power-hungry transceivers and electrical switches in the core of the network. In particular, optical switches based on tunable lasers and arrayed waveguide grating routers are quite promising due to the use of a passive core, which increases fault tolerance and reduces management overhead. Such an OCS-network can offer high bandwidth, low network latency and an energy-efficient and scalable data center network. To support dynamic data center workloads efficiently, however, it is critical to switch between wavelengths at nanosecond (ns) timescales. Here we demonstrate ultrafast OCS based on a microcomb and semiconductor optical amplifiers (SOAs). Using a photonic integrated Si3N4 microcomb, sub-ns (<520 ps) switching along with the 25-Gbps non-return-to-zero (NRZ) and 50-Gbps four-level pulse amplitude modulation (PAM-4) burst mode data transmission is achieved. Further, we use a photonic integrated circuit comprising an Indium phosphide based SOA array and an arrayed waveguide grating to show sub-ns switching (<900 ps) along with 25-Gbps NRZ burst mode transmission providing a path towards a more scalable and energy-efficient wavelength-switched network for data centers in the post Moore's Law era.

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.

BACKGROUND: As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. METHODS: Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. RESULTS: Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. CONCLUSIONS: SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.

Lifelong caloric restriction reprograms hepatic fat metabolism in mice.

Calorie lowering slows the aging process and extends life span in diverse species by so far unknown mechanisms. The inverse linear relationship between calorie intake and life span suggests that regulators of energy metabolism are of importance in aging. The present study shows that lifelong caloric restriction in mice induces a metabolic adaptation with reduced lipogenesis and enhanced lipolysis and ketogenesis. This process, that is, the reprogramming of hepatic fat metabolism, is associated with a marked rise of fibroblastic growth factor 21 as a putative starvation master regulator. Due to the life span-extending properties of fibroblastic growth factor 21, the rise in fibroblastic growth factor 21 might contribute to the markedly better health status found in mice upon lifelong caloric restriction feeding. In addition, adropin, known as a peptide that controls lipid homeostasis, is significantly upregulated, underlining the diminution of lipogenesis that was further substantiated by decreased expression of liver-X-receptor α and its target genes sterol regulatory element-binding protein-1c, fatty acid synthase, and member 1 of human transporter subfamily ABCA upon lifelong caloric restriction feeding.

Lifelong caloric restriction increases working memory in mice.

Caloric restriction (CR) is argued to positively affect general health, longevity and the normally occurring age-related reduction of cognition. This issue is well examined, but most studies investigated the effect of short-term periods of CR. Herein, 4 weeks old female mice were fed caloric restricted for 4, 20 and especially for 74 weeks. CR mice received 60% of food eaten by their ad libitum (AL) fed littermates, and all age-matched groups were behaviorally analyzed. The motor coordination, which was tested by rotarod/accelerod, decreased age-related, but was not influenced by the different periods of CR. In contrast, the age-related impairment of spontaneous locomotor activity and anxiety, both being evaluated by open field and by elevated plus maze test, was found aggravated by a lifelong CR. Measurement of cognitive performance with morris water maze showed that the working memory decreased age-related in AL mice, while a lifelong CR caused a better cognitive performance and resulted in a significantly better spatial memory upon 74 weeks CR feeding. However, a late-onset CR feeding in 66 weeks old mice did not ameliorate the working memory. Therefore, a lifelong CR seems to be necessary to improve working memory.

The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients.

BACKGROUND: There are conflicting data on the usefulness of B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) in the optimization of therapy for heart failure (HF). Discordant results may be explained by the intra-individual variability of these peptides. This study evaluates the intraindividual variability of BNP and NT-proBNP and the impact of the covariates of age, sex, and renal function. METHODS AND RESULTS: Stable HF patients attending our unit were included. Blood samples were drawn 1 hour apart on 2 occasions 1 week apart. Forty-five patients were enrolled (69.6 +/- 12.1 years, 64% male, 84% systolic HF). Within-hour and within-week intraindividual variability were: 6.9% and 21.1% for NT-proBNP; 14.6% and 28.4% for BNP (P < .01 for within-hour comparison of BNP and NT-proBNP). Reference change values over 1 week for NT-proBNP and BNP were 49.2% and 66.2%, respectively. There were no significant relationships identified between variability and age, gender, or glomerular filtration rate. CONCLUSION: There is considerable intraindividual variability in these peptides in stable HF patients. Changes of approximately 50% and 66% for NT-proBNP and BNP from week to week are needed to indicate an altered clinical status and caution should be exercised in interpreting serial changes in these peptide levels when monitoring patient responses to treatment or clinical status.